title: Clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome.
abstract: The aim of study was to evaluate clinical outcome and hormone profiles of laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome (PCOS) before and after treatment. Forty five clomiphene-citrate resistant women with polycystic ovary syndrome underwent laparoscopic electroincision of the ovaries. Serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), androstenedione, 17 OH progesterone and beta endorphins were recorded before and 24 hours after the treatment. Clinical and reproductive outcome and hormone profiles were analyzed. Patients were observed during 12 months period. Laparoscopic electroincision of the ovaries was successfully performed without complications in all patients. LH/FSH ratio was 1,66 24 hours after treatment. Serum levels of T, androstenedione, 17 OH progesterone, and beta endorphins were significantly reduced 24 hours after laparoscopic electroincision of the ovaries. In follow-up period 87% of patients were recorded to have regular menstrual cycles and 61% pregnancy rate was achieved spontaneously. Laparoscopic electroincision of the ovaries is an effective treatment in clomiphene-citrate resistant women with polycystic ovary syndrome. The high pregnancy rate of the procedure offers a promising management for patients with polycystic ovary syndrome.
authors.affiliation: Gynecology and Obstetrics Hospital, University of Sarajevo Clinics Centre, Bolnicka 10, 71000 Sarajevo, Bosnia and Herzegovina.
authors.forename: Zulfo
authors.initials: Z
authors.lastname: Godinjak
authors.forename: Ranka
authors.initials: R
authors.lastname: Javorić
mesh_terms: D000328:Adult; D000735:Androstenedione / Q000097:blood; D002996:Clomiphene / Q000627:therapeutic use; D004351:Drug Resistance; D004598:Electrosurgery / Q000379:methods*; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D010535:Laparoscopy / Q000379:methods*; D007986:Luteinizing Hormone / Q000097:blood; D008597:Menstrual Cycle / Q000502:physiology; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000503:physiopathology / Q000601:surgery*; D011247:Pregnancy; D018873:Pregnancy Rate; D011374:Progesterone / Q000097:blood; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome; D001615:beta-Endorphin / Q000097:blood
chemical_list: D005300:Fertility Agents, Female; D002996:Clomiphene; D013739:Testosterone; D000735:Androstenedione; D011374:Progesterone; D001615:beta-Endorphin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone